Welcome to our dedicated page for Veri MedTech Holdings SEC filings (Ticker: VRHID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Veri MedTech Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Veri MedTech Holdings's regulatory disclosures and financial reporting.
Veri MedTech Holdings, Inc. (VRHID) is pursuing a NASDAQ Capital Market uplisting via a firm-commitment IPO of 3,750,000 shares of common stock at an assumed price of $4.00 per share, with closing conditioned on NASDAQ approval. The company currently trades on the OTC market under “VRHI.”
Veri MedTech is a holding company whose main business, through subsidiary Veriheal, is a telehealth-style platform that helps patients obtain and renew medical cannabis cards in numerous U.S. states, charging roughly $100–$200 per card and renewal. Revenue was about $11 million in 2025 and $17 million in 2024, with net losses of $2.32 million and $0.41 million, respectively; first-half 2026 revenue was $4.48 million with a net loss of $0.50 million.
The company qualifies as an emerging growth company and smaller reporting company and has implemented a 1‑for‑2.5 reverse stock split effective September 2, 2026. Executives hold all Series A preferred stock, which carries 80% of voting power, making Veri MedTech a controlled company. Auditors highlight substantial doubt about its ability to continue as a going concern due to shareholders’ deficit, working-capital deficit, and recurring losses. Net proceeds of roughly $11.95 million are earmarked for organic and acquisitive growth and general corporate purposes.